Prot# CI-PSI-RCV-04-201: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, & Antiviral Effect of Substituting 600mg of Racivir®(RCV) for Lamivudine(3TC) in HIV-Infected Subjects Who Have the M184V Mutati

Project: Research project

Project Details

StatusFinished
Effective start/end date10/25/04 → 3/26/08

Funding

  • Ingenix Pharmaceutical Services, Inc. (CI-PSI-RCV-04-201)
  • Pharmasset, Inc. (CI-PSI-RCV-04-201)